Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Trial will enrol up to 45 patients with solid tumours at UK centres.

e-Therapeutics plc has announced that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

It complements an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California during June.

Like the brain cancer study, the UK trial has a dose-escalating design in which groups of patients receive successively higher doses of the drug.

The primary objective is to evaluate the safety of ETS2101 and identify an appropriate dose for phase II development. Secondary objectives include initial assessment of the drug’s activity and evaluation of its distribution within the body (pharmacokinetics). Final results from the trial are expected during 2013.

Professor Ruth Plummer, Clinical Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research and lead investigator for the phase I study at the Freeman Hospital, Newcastle, said: “ETS2101 derives from an interesting new approach to drug discovery known as network pharmacology. We are pleased to be involved in the first phase of clinical trials evaluating this drug as a potential treatment for cancer.”

e-Therapeutics’ CEO, Professor Malcolm Young, added: “The initiation of a second trial with ETS2101 reflects the growing momentum in our clinical development programme. We hope that the promising preclinical data supporting this drug will ultimately translate into benefits for patients and look forward to seeing the first findings from cancer trials later this year.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

e-Therapeutics Reports Positive Interim Results from UK Phase Ia Trial of ETS2101
ETS2101 well tolerated at all six dose escalations with no serious adverse events attributed to the drug.
Tuesday, April 01, 2014
e-Therapeutics Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder
Company expects to report the results of the trial in the first half of 2015.
Thursday, October 31, 2013
e-Therapeutics to Raise £40 Million
Company to advance lead cancer drug and exploit network pharmacology platform.
Tuesday, February 12, 2013
e-Therapeutics Provides Update on Progress of ETS2101 Cancer Trials
Interim data from the trials are expected in H1 2013.
Monday, December 24, 2012
e-Therapeutics’ ETS2101 Enters Phase I Clinical Trial in Brain Cancer
First findings are expected in late 2012.
Wednesday, June 20, 2012
e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2012
Further drugs for infection and depression expected to enter trials in 2012.
Friday, June 15, 2012
Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
Enrolment of patients into trials will begin shortly.
Thursday, March 29, 2012
e-Therapeutics Outlines Goals for 2012
Company announces presentation at biotech showcase conference.
Thursday, March 01, 2012
Prime Minister Opens e-Therapeutics’ Drug Discovery Centre near Oxford
David Cameron opens Company’s new drug discovery centre at Long Hanborough.
Monday, February 27, 2012
Celgene Executive Dr Rajesh Chopra Joins the Board of e-Therapeutics
Dr Chopra has extensive experience of all phases of drug development.
Monday, February 06, 2012
e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc.
Thursday, July 21, 2011
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!